Skip to main content
Figure 6 | Genetic Vaccines and Therapy

Figure 6

From: The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model

Figure 6

In vivo CTL activity in vaccinated mice. (A) In vivo EGFR-specific effector CTL are located throughout the secondary lymphoid system. A week after last DNA vaccination, an in vivo CTL using recombinant human EGFR protein pulsed splenocytes or inguinal lymph node as targets was performed to assess in vivo CTL activity. (B) The percentages of specific lysis were calculated to obtain a numerical value of cytotoxicity with data from each experimental group of three mice averaged. The symbol(##) and the symbol(**)indicates a statistically significant difference when compared with other treatment groups(P < 0.05). Similar results were obtained from two more repeated experiments (n = 3 per group).

Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556